PregLem SA is a Swiss-based specialty biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine. PregLem is a member of the Richter Group.
PregLem has an experienced senior management team, with a proven track record in developing, registering and commercializing reproductive health products.
ESMYA® (Ulipristal Acetate 5mg)
PregLem’s most advanced product, ESMYA® (Ulipristal Acetate 5mg), is a first-in-class, oral selective progesterone receptor modulator (SPRM) which reversibly blocks the progesterone receptor in its target tissues (uterus, cervix, ovaries, hypothalamus) and acts as a potent, orally active antiprogestational agent. It is registered for long term management of uterine fibroids as well as pre-operative symptoms management.
Research & Development
Uterine fibroids (myoma) are the most common benign, solid tumours of the female genital tract in women of reproductive age. Beyond its physical morbidity, the condition is a frequent cause of significant impairment of quality of life and a leading reason for hysterectomy.
Endometriosis is a benign gynaecological disease characterised by the presence of functional endometrial tissue fragments growing outside the uterus cavity. The major symptoms are chronic pelvic pain, painful menstruations and dyspareunia (painful sexual intercourse).
Infertility is a condition described as the failure to conceive after regular unprotected intercourse. It affects 10 million couples in the EU, 6 million in the USA and 80 million worldwide.
Gedeon Richter and Myovant Sciences Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
31 March 2020 Budapest, Hungary and Basel, Switzerland – Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative…